Endogenous Peptide
Definition
An endogenous peptide is a peptide that is naturally produced within the body as part of normal physiological processes. Examples include GLP-1 (incretin hormone), GnRH/gonadorelin (reproductive hormone), oxytocin (social bonding neuropeptide), and GHK-Cu (wound healing tripeptide). Many research peptides are synthetic analogs of endogenous peptides, modified to improve stability, selectivity, or duration of action.
Related Terms
Related Compounds
Semaglutide
An in-depth review of Semaglutide, a long-acting GLP-1 receptor agonist, covering its mechanism of action, albumin-binding pharmacokinetics, and research applications in metabolic health, weight management, and cardiovascular outcomes.
Read monographGonadorelin
An in-depth review of gonadorelin, the native gonadotropin-releasing hormone (GnRH) decapeptide that regulates the hypothalamic-pituitary-gonadal axis. This monograph covers its mechanism of action at the GnRH receptor on pituitary gonadotrophs, the critical role of pulsatile secretion in differential LH/FSH regulation, pharmacokinetics, diagnostic and research applications, and key published studies.
Read monographOxytocin
Explore the science of oxytocin, the 9-amino-acid neuropeptide known for its roles in social behavior, wound healing, cardioprotection, and metabolic regulation. Comprehensive review of mechanisms, pharmacokinetics, and clinical research.
Read monographGHK-Cu
An in-depth review of GHK-Cu (copper tripeptide), a naturally occurring copper-peptide complex, covering its mechanism of action, research applications in skin regeneration, wound healing, collagen synthesis, and gene expression modulation.
Read monographRelated Studies
Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction
Wu HM, Chang HM, Leung PCK · Frontiers in Neuroendocrinology (2021)
Oxytocin and the neurobiology of prosocial behavior
Marsh N, Marsh AA, Lee MR, et al. · The Neuroscientist (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, et al. · New England Journal of Medicine (2016)